Gamida Cell said today that its NiCord cell graft produces fewer infections, shorter hospital stays and shorter time to engraftment compared to standard umbilical cord blood transplantation.
The company’s work was published in Biology of Blood and Marrow Transplantation.
Get the full story at our sister site, Drug Delivery Business News.
The post Study: Gamida Cell’s NiCord cell graft yields fewer infections, shorter hospital stays appeared first on MassDevice.
from MassDevice http://ift.tt/2p4oEDP
Cap comentari:
Publica un comentari a l'entrada